-
1 Comment
CryoLife, Inc is currently in a long term uptrend where the price is trading 18.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
CryoLife, Inc's total revenue sank by 2.6% to $68M since the same quarter in the previous year.
Its net income has dropped by 407.8% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 284.0% to $3M since the same quarter in the previous year.
Based on the above factors, CryoLife, Inc gets an overall score of 3/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US2289031005 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 2B |
|---|---|
| PE Ratio | 180.56 |
| Target Price | 34.19 |
| Beta | 1.64 |
| Dividend Yield | None |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CYL.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026